Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00189137 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
Phase 2
Development phase
84
Enrollment target

NCT00189137: Completed Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.

NCT00189137 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00189137, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
84 participants
Enrollment target

Study Summary

The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

Primary Outcome

To contrast the proportion of treated patients hospitalized subsequent to treatment with gemcitabine and docetaxel as compared to doxorubicin and ifosfamide as neoadjuvant or adjuvant therapy of poor prognosis soft tissue sarcoma.

Interventions

  • DRUG ifosfamide and doxorubicin vs gemcitabine and docetaxel

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2004-08
Est. Completion 2015-10
Phase Phase 2

What the finished NCT00189137 record still lists

NCT00189137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).

The record links to 0 conditions, and to 1 intervention - of which ifosfamide and doxorubicin vs gemcitabine and docetaxel is the first listed.

NCT00189137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00189137 about?

NCT00189137 is a clinical study titled "Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma". The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

What is the current status of trial NCT00189137?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2004-08. Estimated completion is 2015-10.

What interventions are being tested in trial NCT00189137?

The interventions under investigation include: ifosfamide and doxorubicin vs gemcitabine and docetaxel (DRUG).

Who is sponsoring clinical trial NCT00189137?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00189137's enrollment target sits among peer trials

84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00189137, the US trial registry maintained by the National Library of Medicine. NCT00189137 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.